AL Amyloidosis Therapeutics Market By Product Type (Monoclonal Antibodies, Proteasome Inhibitors, Chemotherapy Agents, Immunomodulatory Drugs, Novel Targeted Therapies); By Treatment Modality (Combination Therapy, Monotherapy, Stem Cell Transplantation Supportive Therapy, Relapse Treatment); By Route of Administration (Subcutaneous, Intravenous, Oral); By End User (Hospitals, Specialty Hematology and Oncology Clinics, Outpatient Infusion Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

AL Amyloidosis Therapeutics Market: Daratumumab Standardization, Recurring Treatment, and Targeted Pipeline Expansion Accelerate Revenue Growth

The Global AL Amyloidosis Therapeutics Market is estimated at USD 3.58 billion in 2025 and is projected to reach USD 8.11 billion by 2032, expanding at a CAGR of 12.4%, according to Strategic Market Research.

 

Revenue growth is concentrated in recurring plasma-cell-directed therapy rather than surgery or one-time procedures. Daratumumab-based combinations generate the largest branded value, while proteasome inhibitors, chemotherapy, immunomodulatory drugs, and emerging targeted therapies support treatment before transplantation, in transplant-ineligible patients, and after relapse.

 

The commercial structure became more stable on November 19, 2025, when the U.S. FDA granted traditional approval to Darzalex Faspro—daratumumab and hyaluronidase-fihj—in combination with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed AL amyloidosis. The indication had operated under accelerated approval since 2021. Darzalex Faspro remains the only FDA-approved AL-specific therapy, giving Johnson & Johnson a concentrated position in first-line treatment and reinforcing monoclonal antibodies as the market’s largest drug class.

 

A Rare-Disease Population Produces High Recurring Pharmaceutical Revenue

A 2025 U.S. electronic health-record analysis identified 1,976 adults with AL amyloidosis and estimated 2021 incidence at 16.7 cases per million adult person-years. Prevalence reached 69.0 cases per million adults. Applying these rates to the 2021 U.S. adult population produces an estimated 4,316 newly recorded adult cases annually and approximately 17,831 prevalent adults. These calculated populations represent recorded disease burden rather than national treated-patient counts.

Commercial demand is smaller than the epidemiological population because a patient must receive the correct amyloid typing, reach a specialist center, satisfy treatment criteria, obtain reimbursement approval, and remain clinically stable enough to continue therapy. Patients in remission, receiving observation, undergoing stem-cell transplantation, or unable to tolerate treatment do not generate the same pharmaceutical demand as patients receiving repeated combination cycles.

The patient population is also concentrated in older adults with substantial organ involvement. The U.S. study recorded heart failure in 38% of prevalent patients and 41% of incident patients. These comorbidities move treatment toward hospital hematology departments and specialist amyloidosis centers, where cardiac, renal, and hematologic services can be coordinated. High-acuity management supports premium treatment expenditure but can shorten therapy duration when patients present too late for sustained treatment.

 

Daratumumab Has Rewritten the First-Line Revenue Model

Daratumumab changed AL amyloidosis from a treatment market built around variable plasma-cell regimens into one with a clearly defined commercial first-line pathway. The approved combination places a premium anti-CD38 antibody alongside bortezomib, cyclophosphamide, and dexamethasone, followed by daratumumab continuation for eligible patients.

The final ANDROMEDA analysis found that adding daratumumab to VCd produced deeper and faster hematologic responses, improved organ recovery, and generated statistically significant gains in overall survival and major organ deterioration-progression-free survival. The initial randomized study enrolled 388 newly diagnosed patients, providing an unusually large regulatory evidence base for a rare plasma-cell disorder.

Commercial value extends beyond the initial combination cycles. Daratumumab can continue after the VCd components are completed, creating repeated subcutaneous administrations over a longer treatment period. Revenue therefore depends on treatment initiation, continuation, tolerability, survival, and payer authorization rather than the number of newly diagnosed patients alone.

The wider Darzalex platform provides Johnson & Johnson and Genmab with manufacturing scale, prescriber familiarity, and established payer relationships. Worldwide Darzalex net sales across all indications reached USD 14.351 billion in 2025, compared with USD 11.670 billion in 2024. AL amyloidosis revenue is not separately disclosed, but the platform’s scale gives the incumbent resources to support specialist education, evidence generation, market access, and formulation development.

 

Reimbursement Converts Clinical Eligibility into Actual Drug Volume

Australia provides direct evidence of the recurring demand created by public reimbursement. Following the January 2023 Pharmaceutical Benefits Scheme listing, AL amyloidosis utilization increased from 294 patients and 3,270 prescriptions in 2023 to 443 patients and 4,881 prescriptions in 2024. The 2024 figures represent approximately 11 prescriptions per reported patient.

The 51% increase in Australian patients during the first two reporting years reflects reimbursement-led uptake rather than underlying disease incidence growth. It also demonstrates how market access can release previously constrained demand once prescribers have a nationally funded treatment pathway.

England and Wales introduced another major access route when NICE recommended daratumumab in combination for newly diagnosed systemic AL amyloidosis in March 2024. NICE reported a list price of GBP 4,320 per 1,800 mg vial, excluding VAT, while confirming that a commercial access arrangement applies to NHS procurement. The difference between the public list price and confidential net terms allows the supplier to maintain a premium reference value while addressing payer concerns over affordability and cost effectiveness.

Treatment adoption remains payer-sensitive even after regulatory approval. U.S. demand is influenced by medical-benefit coverage, hospital reimbursement, administration payments, and prior authorization. European uptake varies by national health-technology assessment and hospital funding. Canadian commercialization depends on provincial implementation of reimbursement recommendations, while utilization in several Asia-Pacific markets remains constrained by diagnostic access and public funding.

 

Diagnostic Delay Removes Patients from the Commercial Treatment Funnel

Diagnosis remains one of the largest barriers between disease prevalence and treated demand. A 2026 patient survey found that 59% of respondents experienced a diagnostic delay, while 35% waited longer than 12 months. Approximately half attributed the delay to insufficient provider awareness.

Prolonged diagnosis does not merely postpone revenue. It allows cardiac and renal involvement to progress, increasing the probability of hospitalization, treatment intolerance, early mortality, and exclusion from standard regimens. A 40-year U.S. longitudinal study of 2,337 patients found that six-month mortality declined from 23% to 13%, but the remaining early-death rate continues to remove patients before they can receive sustained treatment.

The American Society of Hematology published dedicated AL amyloidosis diagnostic guidelines in January 2026. The recommendations support serum and urine testing for monoclonal proteins and free light chains, followed by bone-marrow biopsy and fat-pad sampling in appropriate patients. Standardized testing can improve referral quality and reduce confusion between AL amyloidosis and ATTR amyloidosis, which follows a different therapeutic and commercial pathway.

Companies selling AL therapies therefore depend on more than hematologist awareness. Commercial expansion requires referral networks involving cardiologists, nephrologists, neurologists, pathologists, and primary-care providers who may encounter organ-specific manifestations before the plasma-cell disorder is recognized.

 

Advanced Cardiac Disease Remains the Largest Untreated Commercial Gap

Cardiac involvement determines treatment urgency, tolerance, and survival. Patients with the most advanced cardiac disease were excluded from the pivotal ANDROMEDA trial, leaving a high-mortality subgroup outside the strongest randomized evidence base.

Recent research continues to evaluate whether rapid plasma-cell suppression can improve outcomes in Stage IIIB disease. A Phase II study of daratumumab monotherapy in previously untreated Stage IIIB patients reported a six-month overall-survival rate of 65% and a median overall survival of 10.4 months. The best hematologic response rate reached 75%, but serious events included cardiac failure, sudden cardiac death, and acute kidney injury. The findings support the commercial need for fast-acting treatments while demonstrating the difficulty of maintaining high-risk patients on therapy.

Advanced cardiac AL is strategically valuable because current treatment choices are limited and mortality is high. It is also commercially difficult because early deaths, treatment interruptions, and organ instability reduce the number of completed cycles. Products designed for this population must demonstrate rapid hematologic control without imposing additional cardiac burden.

 

Stem-Cell Transplantation Supports Rather Than Displaces Pharmaceutical Demand

Autologous stem-cell transplantation remains relevant for selected patients, but only approximately 20%–30% of newly diagnosed patients are estimated to qualify. Eligibility depends on age, cardiac status, renal function, performance status, and access to an experienced transplant center.

Drug therapy and transplantation generally operate sequentially. Patients may receive plasma-cell-directed induction before transplantation, while those achieving a deep response may defer transplantation until relapse. The larger transplant-ineligible population remains dependent on systemic pharmaceutical treatment.

The market is therefore measured more effectively through treated patients, injections, prescriptions, cycles, and treatment duration than through surgical procedure counts. Even transplant-eligible patients can contribute to proteasome-inhibitor, antibody, chemotherapy, and relapse-treatment revenue before and after the procedure.

 

Segment Revenue Analysis

Strategic Market Research has allocated the USD 3.58 billion market across drug class, route of administration, end user, and geography using the approved treatment pathway, regimen composition, administration schedules, public utilization evidence, care-setting patterns, and likely pipeline entry. The individual segment estimates reconcile with the total market in both 2025 and 2032.

Drug Class Analysis

Monoclonal antibodies represent the largest drug-class segment, accounting for an estimated 44% of the market and USD 1.58 billion in 2025. The segment is projected to reach approximately USD 3.81 billion by 2032, equal to 47% of total revenue and an implied CAGR of 13.5%. Daratumumab’s AL-specific approval, premium pricing, repeated administration, and continuation schedule concentrate the largest portion of market value in this category. Future anti-fibril antibodies or additional anti-CD38 therapies could broaden the segment beyond a single incumbent.

Proteasome inhibitors account for approximately 25% of the market and USD 0.90 billion in 2025. Segment revenue is projected to reach USD 1.70 billion by 2032, despite its share declining to 21%, producing an implied CAGR of 9.6%. Bortezomib remains embedded in the approved first-line regimen and is also used in other induction and relapse combinations. Its relative share declines because mature proteasome inhibitors capture less incremental value than branded antibodies and new precision therapies.

Chemotherapy represents an estimated 14% share and USD 0.50 billion in 2025. Revenue is projected to increase to approximately USD 0.81 billion by 2032, although the segment’s share is expected to fall to 10%, corresponding to an implied CAGR of 7.1%. Cyclophosphamide remains part of the approved VCd backbone, while melphalan retains selected use in transplantation and alternative regimens. Mature pricing and limited product differentiation restrain revenue growth relative to biologics.

Immunomodulatory drugs account for approximately 10% of the market and USD 0.36 billion in 2025. The segment is expected to reach USD 0.65 billion by 2032, representing an 8% share and an implied CAGR of 8.9%. Lenalidomide and pomalidomide remain relevant in selected relapsed patients, but organ dysfunction and tolerability concerns limit broad use. A European retrospective series of 153 relapsed or refractory patients found that pomalidomide-based treatment could produce rapid hematologic responses, supporting continued later-line demand without establishing it as a universal standard.

Novel targeted therapies represent the smallest but fastest-growing drug-class segment. Revenue is estimated at USD 0.25 billion in 2025, equivalent to 7% of the market, and is projected to reach approximately USD 1.14 billion by 2032, representing 14% of total revenue and an implied CAGR of 24.1%. The category includes anti-fibril antibodies, BCMA-directed therapies, BCL-2 inhibitors for biomarker-defined patients, and other precision approaches. The estimate assumes selective clinical and regulatory success rather than approval of every current candidate.

 

Route of Administration Analysis

Subcutaneous administration dominates the market, generating an estimated USD 1.72 billion in 2025, equal to 48% of global revenue. The segment is projected to reach approximately USD 4.22 billion by 2032, representing 52% of the market and an implied CAGR of 13.7%. Darzalex Faspro and commonly used subcutaneous bortezomib place the main first-line components within this route. Short administration times, lower infusion-chair use, and suitability for specialist outpatient care support its expanding share.

Intravenous administration accounts for an estimated 30% share and USD 1.07 billion in 2025. Revenue is projected to reach approximately USD 2.51 billion by 2032, representing 31% of the market and an implied CAGR of 12.9%. Intravenous demand is supported by selected proteasome inhibitors, supportive therapies, investigational anti-fibril antibodies, and later-line treatments requiring supervised administration.

Oral administration represents approximately 22% of the market and USD 0.79 billion in 2025. The segment is expected to grow to USD 1.38 billion by 2032, although its market share is projected to decline to 17%, producing an implied CAGR of 8.3%. Oral cyclophosphamide, dexamethasone, immunomodulatory drugs, ixazomib, and targeted agents support continued demand, but the highest-value approved products remain injectable.

 

End-User Analysis

Hospitals account for the largest end-user segment, representing approximately 52% of the market and USD 1.86 billion in 2025. Hospital revenue is projected to reach USD 3.81 billion by 2032, although its share is expected to decline to 47%, corresponding to an implied CAGR of 10.8%. Hospitals retain leadership because newly diagnosed patients frequently require cardiac and renal evaluation, pathology, infusion services, inpatient stabilization, and transplant assessment.

Specialty hematology and oncology clinics generate an estimated USD 1.07 billion in 2025, equivalent to 30% of total market revenue. The segment is projected to reach approximately USD 2.68 billion by 2032, representing 33% of the market and an implied CAGR of 13.9%. Specialist clinics benefit from concentrated prescriber expertise, repeated monitoring, subcutaneous administration, and the movement of clinically stable patients away from full hospital settings.

Outpatient infusion centers account for approximately 18% of the market and USD 0.64 billion in 2025. Revenue is projected to reach USD 1.62 billion by 2032, increasing the segment’s share to 20% and producing an implied CAGR of 14.1%. Growth depends on payer support for lower-cost sites of care, expanding infusion capacity, and the ability to transfer stable patients from hospital departments to scheduled outpatient treatment.

 

Regional Analysis

North America leads the global market with an estimated 45% share and USD 1.61 billion in 2025. Regional revenue is projected to reach approximately USD 3.49 billion by 2032, representing 43% of the global market and an implied CAGR of 11.7%. FDA approval, premium drug pricing, medical-benefit reimbursement, and a network of specialist amyloidosis centers support regional leadership.

Europe accounts for approximately 29% of global revenue and USD 1.04 billion in 2025. The regional market is projected to reach USD 2.27 billion by 2032, equivalent to a 28% share and an implied CAGR of 11.8%. European growth is supported by centralized regulatory authorization, national health-technology assessments, specialist referral centers, and reimbursement decisions such as NICE TA959. Country-level price negotiations continue to create uneven treatment access.

Asia-Pacific represents an estimated 19% share and USD 0.68 billion in 2025. Revenue is projected to reach approximately USD 1.78 billion by 2032, increasing the regional share to 22% and producing the fastest regional CAGR of 14.8%. Australia already demonstrates measurable reimbursement-led adoption, while Japan, China, South Korea, and other markets offer growth through improved disease recognition, expanding hematology infrastructure, and broader access to biologics.

Latin America accounts for approximately 4% of the market and USD 0.14 billion in 2025. The region is projected to reach USD 0.32 billion by 2032, maintaining a 4% share and expanding at approximately 12.4% annually. Growth will remain concentrated in private hospitals, major urban oncology centers, and public systems capable of funding high-cost rare-disease therapies.

The Middle East and Africa represent approximately 3% of global revenue and USD 0.11 billion in 2025. The regional market is expected to reach approximately USD 0.24 billion by 2032, maintaining a 3% share and an implied CAGR of 12.4%. Demand is led by specialist centers in Gulf countries, Israel, South Africa, and selected academic hospitals, while diagnostic access and reimbursement remain major constraints across lower-income markets.

 

Competitive Landscape and Key Players

Johnson & Johnson and Genmab Control the Approved First-Line Platform

Johnson & Johnson, through Janssen Biotech, holds the strongest commercial position with Darzalex Faspro. The product’s traditional FDA approval, first-line guideline position, subcutaneous formulation, and international reimbursement create a substantial competitive barrier.

Genmab remains strategically important as the originator and licensing partner behind daratumumab. Its royalty-based participation links the company to the wider Darzalex franchise, which generated USD 14.351 billion in worldwide sales across all indications in 2025. Johnson & Johnson controls commercialization, while Genmab benefits from the platform’s continued growth.

Johnson & Johnson is also positioned to extend its role beyond CD38 targeting. Phase II studies are evaluating the BCMA×CD3 bispecific antibody teclistamab in previously treated AL amyloidosis and in combination with daratumumab. These programs could create a later-line franchise if deep plasma-cell responses can be achieved without unacceptable infection or cytokine-release risks.

 

AstraZeneca and Alexion Pursue Anti-Fibril Differentiation

AstraZeneca’s Alexion rare-disease division is developing anselamimab as an anti-fibril antibody intended to target existing amyloid deposits rather than only suppress their plasma-cell source. The CARES Phase III program enrolled 406 patients with advanced cardiac AL amyloidosis across 19 countries.

The program did not meet its primary endpoint in the overall population. AstraZeneca nevertheless reported a 62% reduction in all-cause mortality and a 71% reduction in cardiovascular hospitalizations in the prespecified kappa light-chain subgroup. These findings could support a biomarker-defined development strategy, but the overall trial failure leaves regulatory and reproducibility risk.

 

Takeda Retains a Position in Proteasome-Inhibitor Treatment

Takeda participates through bortezomib-related treatment exposure and the oral proteasome inhibitor ixazomib. The Phase III TOURMALINE-AL1 study enrolled 168 patients with relapsed or refractory AL amyloidosis and compared ixazomib plus dexamethasone with physician-selected therapy. Although ixazomib did not establish a new universal AL standard, it remains relevant for selected patients requiring an oral proteasome-inhibitor option.

 

Sanofi Provides a Potential Second Anti-CD38 Platform

Sanofi is an emerging competitive participant through isatuximab. The prospective SWOG S1702 Phase II study evaluated isatuximab monotherapy in relapsed or refractory AL amyloidosis, supporting continued investigation of anti-CD38 competition beyond daratumumab. Isatuximab does not currently hold an AL-specific approval, leaving Johnson & Johnson’s first-line position intact.

Sanofi’s development of subcutaneous isatuximab for multiple myeloma also creates a formulation platform that could become relevant to AL amyloidosis if future trials support use in the disease. The company received U.S. approval for the on-body-injector formulation in July 2026 across existing multiple myeloma indications, demonstrating its ability to compete on administration convenience.

 

Bristol Myers Squibb Supports the Relapsed Immunomodulatory Segment

Bristol Myers Squibb participates through lenalidomide and pomalidomide, which are used selectively in relapsed or refractory AL amyloidosis. A 153-patient European retrospective series found activity with pomalidomide and dexamethasone in heavily pretreated patients, supporting a continuing role when patients have exhausted proteasome-inhibitor or antibody-based options. Use remains individualized because cardiac and renal toxicity can restrict suitability.

 

AbbVie Represents the Biomarker-Defined BCL-2 Opportunity

AbbVie’s venetoclax is commercially relevant to the high-frequency t(11;14) biological subgroup, although the product does not have an AL-specific FDA indication. A multicenter retrospective cohort of 43 previously treated AL patients found deep hematologic responses with venetoclax, particularly in t(11;14)-positive disease. More recent evidence continues to position the translocation as a clinically distinct subgroup with potential for precision-directed treatment.

 

GSK and Other BCMA Developers Target Post-Daratumumab Disease

GSK has participated through clinical studies of belantamab mafodotin in relapsed or refractory AL amyloidosis. BCMA-directed antibodies, antibody-drug conjugates, bispecific antibodies, and cellular therapies could create a new later-line segment because treatment after frontline daratumumab remains fragmented. Current programs remain early-stage and must demonstrate acceptable safety in patients with cardiac, renal, or multisystem involvement.

 

Prothena’s Exit Shows the Risk of Anti-Fibril Development

Prothena was a major anti-fibril competitor through birtamimab, but the Phase III AFFIRM-AL study failed to meet its primary endpoint. The company discontinued development after reporting a hazard ratio of 0.915 and a p-value of 0.768. The exit reduced late-stage competition while demonstrating that amyloid-depletion mechanisms require convincing survival or hospitalization evidence rather than biomarker improvement alone.

 

Strategic Market Outlook

The AL amyloidosis therapeutics market will expand through higher treatment conversion, longer survival, recurring antibody administration, broader reimbursement, and the gradual addition of precision therapies. Disease incidence alone cannot support a 12.4% market CAGR. Growth requires more patients to receive an accurate diagnosis before advanced organ failure and to remain on treatment long enough to generate recurring pharmaceutical demand.

Daratumumab-based therapy will remain the principal revenue foundation through the near term. Traditional FDA approval, final survival evidence, international reimbursement, and a commercially established subcutaneous formulation support continued leadership by Johnson & Johnson and Genmab.

Novel targeted therapies provide the largest incremental opportunity. Anti-fibril antibodies could add organ-directed treatment to plasma-cell suppression, while venetoclax, BCMA-directed therapies, and other precision approaches could address biologically defined or post-daratumumab populations. Recent Phase III failures confirm that pipeline revenue will be concentrated among a small number of clinically successful products rather than distributed across every experimental mechanism.

Hospitals will remain the largest purchasing setting, but specialty clinics and outpatient infusion centers will gain share as subcutaneous administration and site-of-care optimization move stable patients away from inpatient infrastructure. Asia-Pacific will record the strongest regional expansion as diagnosis, specialist capacity, and reimbursement improve.

Companies that combine rapid hematologic control, measurable organ benefit, manageable cardiac safety, convenient administration, and payer-supported treatment duration will capture the largest portion of the projected USD 8.11 billion market by 2032.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.58 Billion
Revenue Forecast in 2032	USD 8.11 Billion
Overall Growth Rate	CAGR of 12.4%
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Product Type	Monoclonal Antibodies; Proteasome Inhibitors; Chemotherapy Agents; Immunomodulatory Drugs; Novel Targeted Therapies
By Treatment Modality	Combination Therapy; Monotherapy; Stem Cell Transplantation Supportive Therapy; Relapse Treatment
By Route of Administration	Subcutaneous; Intravenous; Oral
By End User	Hospitals; Specialty Hematology and Oncology Clinics; Outpatient Infusion Centers
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Growth of Daratumumab-Based Treatment	Increasing adoption of daratumumab-based combinations and regulatory approvals are strengthening the role of monoclonal antibodies as the leading revenue contributor in AL amyloidosis treatment.
Market Drivers – Rising Focus on Rare Disease Management	Growing diagnosis efforts, specialist referral networks, and improved treatment pathways are increasing the number of patients entering long-term therapeutic management.
Market Drivers – Expansion of Targeted Therapy Pipeline	Development of anti-fibril antibodies, BCMA-directed therapies, and biomarker-driven treatments is creating new opportunities beyond conventional plasma-cell-directed regimens.
Customization Option	Available upon request